Alnylam Pharmaceuticals: Pipeline Expansion In Neurodegenerative Diseases As A Pivotal Factor Driving Growth! 

Alnylam Pharmaceuticals demonstrated strong financial and operational performance in its Q3 2024 results, marking a significant phase of growth and expansion across its product and pipeline portfolios. The company reported a 34% year-over-year increase in global net product revenue, totaling $420 million. This growth is predominantly attributed to the robust performance of its TTR franchise, which alone generated $309 million, reflecting a 34% increase from the previous year.